vimarsana.com

Page 46 - ஆல்பர்ட் ஐன்ஸ்டீன் கல்லூரி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The American College of Medical Genetics and Genomics Elects New Board Members, President-Elect

Share this article Share this article BETHESDA, Md., April 12, 2021 /PRNewswire/ The American College of Medical Genetics and Genomics (ACMG) welcomed five new directors, including a new president-elect, to its Board of Directors at the 2021 ACMG Annual Clinical Genetics Meeting – A Virtual Experience. The new Board members will serve as advocates for the organization and will assist in shaping and implementing the mission, vision, and direction of the College. The five newly elected directors will serve six-year terms from April 2021 to March 2027. I have enjoyed the chance to meet our recently elected Board members. Each of them offers unique perspectives, new insights and opportunities to advance ACMG s strategic plan, said Anthony Gregg, MD, MBA, FACMG, president of the ACMG. I hope every ACMG member feels comfortable reaching out to the Board with the goal of moving our strategic plan forward. There are many ways to plug in.

Who is Dr Jonathan Rich? All about the cardiologist from Derek Chauvin case

Who is Dr Jonathan Rich? All about the cardiologist from Derek Chauvin case   Dr Jonathan Rich is a cardiologist who testified in the Derek Chauvin trial. He stated: “I believe that Mr George Floyd’s death was absolutely preventable.” During his testimony, Dr Rich said “with a high level of medical certainty that George Floyd did not die from a primary heart event, and he did not die from a drug overdose.” He is not the first medical expert in this trial to state that George Floyd’s death could have been prevented. This content could not be loaded A cardiologist testifying at Derek Chauvin s trial, after examining the possible causes of #GeorgeFloyd s death:

Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21

Press release content from Business Wire. The AP news staff was not involved in its creation. Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21 April 10, 2021 GMT PALO ALTO, Calif. (BUSINESS WIRE) Apr 10, 2021 Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today the first public presentation of preclinical data for its first-in-class myeloid checkpoint inhibitor, IO-202, an LILRB4 antagonist antibody, in solid tumors. The electronic poster will be presented as part of the Immune Checkpoints Session of the American Association for Cancer Research (AACR) Annual Meeting 2021 (#AACR21), taking place virtually April 10-15, 2021.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.